| HARMONY-BIOSCIENCES |
HARMONY-BIOSCIENCES |
92%
|
Out-licensed intellectual property to Harmony Biosciences in January 2026 |
| CUSTOMER-1 |
CUSTOMER-1 |
90%
|
Customer 1 accounted for 17% of net revenues during the three months ended March 31, 2026 |
| CUSTOMER-2 |
CUSTOMER-2 |
90%
|
Customer 2 accounted for 10% of net revenues during the three months ended March 31, 2026 |
| CUSTOMER-3 |
CUSTOMER-3 |
90%
|
Customer 3 accounted for 16% of net revenues during the three months ended March 31, 2026 |
| CUSTOMER-4 |
CUSTOMER-4 |
90%
|
Customer 4 accounted for 18% of net revenues during the three months ended March 31, 2026 |
| EMMA |
Emmaus Life Sciences, Inc. |
72%
|
Reciprocal relationship from EMMA graph: Reciprocal relationship from ANIP graph: Reciprocal relationship from EMMA graph: Reciprocal relationship from ANIP graph: Reciprocal relationship from EMMA g… |
| EYPT |
EyePoint, Inc. |
72%
|
Reciprocal relationship from EYPT graph: financial statements. It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies d… |
| ANIP-ACQUISITION-COMPANY |
ANIP-ACQUISITION-COMPANY |
62%
|
trative Fees and Other Rebates and $ 7.2 million of Prompt Payment Discounts. Administrative Fees and Other Rebates of $ 7.7 million is included in accrued expenses and other in the unaudited condens… |
| ESJAY-PHARMA-PRIVATE-LIMITED |
ESJAY-PHARMA-PRIVATE-LIMITED |
62%
|
y paid the final quarterly payment of $ 1.9 million. Upon making the quarterly payments in the aggregate amount of $ 7.5 million in 2024, the licenses and rights granted to the Company became automat… |
| HARMONY-BIOSCIENCES-LLC |
HARMONY-BIOSCIENCES-LLC |
62%
|
78 Other generic revenues 3,818 4,362 Generics and Other total net revenues 109,220 103,040 Total net revenues $ 237,462 $ 197,122 ____________________________________________ (1) There were no sales… |
| NOVITIUM-PHARMA-LLC |
NOVITIUM-PHARMA-LLC |
62%
|
78 Other generic revenues 3,818 4,362 Generics and Other total net revenues 109,220 103,040 Total net revenues $ 237,462 $ 197,122 ____________________________________________ (1) There were no sales… |
| NURAY-CHEMICAL-PRIVATE-LIMITED |
NURAY-CHEMICAL-PRIVATE-LIMITED |
62%
|
y paid the final quarterly payment of $ 1.9 million. Upon making the quarterly payments in the aggregate amount of $ 7.5 million in 2024, the licenses and rights granted to the Company became automat… |
| NURAY-CHEMICALS-PRIVATE-LIMITED |
NURAY-CHEMICALS-PRIVATE-LIMITED |
62%
|
2026 December 31, 2025 Remaining Weighted Average Amortization Period (1) (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortizat… |
| SS-PHARMA-LLC |
SS-PHARMA-LLC |
62%
|
y paid the final quarterly payment of $ 1.9 million. Upon making the quarterly payments in the aggregate amount of $ 7.5 million in 2024, the licenses and rights granted to the Company became automat… |
| STHREE-CHEMICALS-PVT-LTD |
STHREE-CHEMICALS-PVT-LTD |
62%
|
y paid the final quarterly payment of $ 1.9 million. Upon making the quarterly payments in the aggregate amount of $ 7.5 million in 2024, the licenses and rights granted to the Company became automat… |
| U-S-BANK-TRUST-COMPANY |
U-S-BANK-TRUST-COMPANY |
62%
|
trative Fees and Other Rebates and $ 7.2 million of Prompt Payment Discounts. Administrative Fees and Other Rebates of $ 7.7 million is included in accrued expenses and other in the unaudited condens… |
